Posted 11/1/2023, 7:00:00 AM
AstraZeneca Invests $245M in Cellectis For Novel Cell and Gene Therapy Collaboration
- Cellectis and AstraZeneca enter into collaboration and investment agreements to develop novel cell & gene therapies
- AstraZeneca to invest up to $245M in Cellectis ($220M equity, $25M upfront) with potential milestones and royalties
- Collaboration to leverage Cellectis' gene editing and manufacturing capabilities for up to 10 candidate products
- AstraZeneca receives exclusive license option on candidates before IND filing
- Cellectis to receive up to $220M per candidate in milestones plus royalties; to use proceeds to develop gene editing tools and programs
